Bacteria that normally live in and upon us have genetic blueprints that enable them to make thousands of molecules that act like drugs, and some of these molecules might serve as the basis for new human therapeutics, according to UCSF researchers.
September 11, 2014
February 26, 2014
Researchers worldwide will now have access to genetic data linked to medical information on a diverse group of more than 78,000 people, enabling investigations into many diseases and conditions.
February 23, 2014
Scientists at the Gladstone Institutes and UCSF have made an important breakthrough: they have discovered a way to transform skin cells into mature, fully functioning liver cells that flourish.
February 20, 2014
Scientists at the UCSF-affiliated Gladstone Institutes have devised a new method that allows for the more efficient and complete reprogramming of skin cells into cells that are virtually indistinguishable from heart muscle cells.
April 29, 2013
Susan Desmond-Hellmann, MD, MPH The pharmaceutical industry gets a bad rap for having a corrupting influence on clinical trials, but that perception undermines the many scientific breakthroughs that have come from industry-backed research, according to UC San Francisco’s chancellor.
December 13, 2011
UCSF Chancellor Susan Desmond-Hellmann, MD, former president for product development at Genentech, is featured in a video interview for BioCentury Publications Inc., a major biopharmaceutical news media source, which first aired online on Dec. 11.
June 30, 2011
Erik Lium has been named assistant vice chancellor of UCSF's newly created Office of Innovation, Technology and Alliances to provide the strategic leadership to both support innovation on campus and foster external alliances to advance biomedical research.
May 05, 2011
Yervoy, a new cancer drug that has been approved for the treatment of late-stage melanoma – and that is being used to treat other cancers in ongoing clinical trials – is based on a strategy for boosting the immune response developed and tested by scientists from UCSF and UC Berkeley.
February 28, 2011
UCSF and Zcube have entered into a new agreement to license UCSF-developed microtechnology and support early research into new ways to deliver oral medications directly to a targeted site in the body.
February 24, 2011
The California Institute for Quantitative Biosciences (QB3) at Mission Bay celebrates a decade of driving the bioeconomy and spells out its goal of helping the state foster science and innovation to benefit society.